Retagliptin
- Generic Name
- Retagliptin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F6N4O3
- CAS Number
- 1174122-54-3
- Unique Ingredient Identifier
- 328C4R3P9L
- Background
Retagliptin is under investigation in clinical trial NCT02822534 (The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients).
- Indication
用于改善成人2型糖尿病患者的血糖控制。
①单药：本品单药可配合饮食控制和运动，改善成人2型糖尿病患者的血糖控制。
②与盐酸二甲双胍联合使用：在单独使用盐酸二甲双胍血糖控制不佳时，本品可与盐酸二甲双胍联合使用，配合饮食和运动改善成人2型糖尿病患者的血糖控制。
A Trial of SP2086 With Hepatic Insufficiency
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06035406
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT05054842
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02826044
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02821871
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02822534
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
The DDI Study of SP2086 and Simvastatin
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02817243
- Locations
- 🇨🇳
the First Hosital of Jilin University, Changchun, Jilin, China
The DDI Study of SP2086 and Valsartan
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02817217
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, Sichuan, China
The Drug -Drug Interaction of SP2086 and Glyburide
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02815787
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
The Metabolite Identification and Material Balance Study of SP2086
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT02815748
The Drug-drug Interaction of SP2086 and Valsartan
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02815657
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.